Valuation: Opus Genetics, Inc.

Market Cap 312M 270M 252M 232M 438M 29.68B 442M 2.96B 1.16B 14.85B 1.17B 1.15B 49.18B P/E 2026 *
-3.49x
P/E 2027 * -4.97x
Enterprise Value 312M 270M 252M 232M 438M 29.68B 442M 2.96B 1.16B 14.85B 1.17B 1.15B 49.18B EV / Sales 2026 *
21x
EV / Sales 2027 * 21.3x
Free-Float
88.97%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+1.89%
1 week+8.93%
Current month+1.89%
1 month-10.64%
3 months-27.31%
6 months+46.51%
Current year+88.06%
1 week 3.54
Extreme 3.54
3.86
1 month 2.82
Extreme 2.82
4.24
Current year 1.88
Extreme 1.88
5.81
1 year 1.04
Extreme 1.04
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap.
23/7/26 Sell

Chief Financial Officer

-7,783 0.0094%
23/7/26 Sell

Chairperson

-7,429 0.0090%
23/7/26 Sell

Chief Executive Officer

-9,475 0.0115%
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+8.93%+240.54%-5.74% 312M
+4.86%-3.32%+52.73%+160.26% 1,043B
+1.04%-2.99%+50.87%+52.38% 621B
+0.98%-6.49%+24.00%+66.66% 435B
+1.06%+4.27%+48.23%+39.14% 361B
+0.98%-1.03%+35.84%+39.65% 293B
+0.44%-5.13%+9.17%+10.86% 251B
+4.57%+5.21%+35.91%+67.64% 220B
-0.04%-11.74%+0.88%-46.48% 201B
-2.58%-0.73%+17.16%+67.46% 164B
Average +0.91%-2.54%+51.53%+45.18% 358.95B
Weighted average by Cap. +0.87%-3.79%+38.50%+76.27%

Financials

2026 *2027 *
Net sales 14.87M 12.88M 12.01M 11.04M 20.85M 1.41B 21.08M 141M 55.37M 707M 55.85M 54.62M 2.34B 14.64M 12.68M 11.82M 10.87M 20.52M 1.39B 20.75M 139M 54.52M 697M 54.99M 53.78M 2.31B
Net income -95.75M -82.93M -77.31M -71.1M -134M -9.1B -136M -908M -357M -4.56B -360M -352M -15.09B -68.34M -59.19M -55.18M -50.75M -95.8M -6.5B -96.87M -648M -254M -3.25B -257M -251M -10.77B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
05/08/26 USD 3.780 +1.89% 872,254
04/08/26 USD 3.710 +1.92% 718,461
03/08/26 USD 3.640 -1.89% 1,731,481
31/07/26 USD 3.710 -3.39% 970,579
30/07/26 USD 3.840 +10.66% 1,037,225
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
3.780USD
Average target price
10.61USD
Spread / Average Target
+180.72%

Quarterly revenue - Rate of surprise